Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 7.48 is 21% above its 5-year average of 6.18, around the middle of its 5-year range (1.33–13.33).
As of the fiscal period ended Tuesday, June 30, 2026. 21.78% below its 12-month average of 9.56.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 7.48.
QUICK RATIO (ACID-TEST)
7.48
QUICK RATIO (ACID-TEST) AVG TTM
9.56
QUICK RATIO (ACID-TEST) AVG 3Y
7.55
QUICK RATIO (ACID-TEST) AVG 5Y
6.18
QUICK RATIO (ACID-TEST) AVG 10Y
5.37
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-21.78%
CURRENT VS 3Y AVG
-0.93%
CURRENT VS 5Y AVG
+20.88%
CURRENT VS 10Y AVG
+39.30%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+123.14%
vs the sector median at left
Cartesian Therapeutics, Inc.
Market Cap
$198.33M
Quick Ratio (Acid-Test)
7.48
TTM Avg
9.56
3Y Avg
7.55
5Y Avg
6.18
Market Cap
$197.18M
Quick Ratio (Acid-Test)
12.14
TTM Avg
7.27
3Y Avg
7.16
5Y Avg
7.21
Market Cap
$200.96M
Quick Ratio (Acid-Test)
5.26
TTM Avg
3.62
3Y Avg
4.54
5Y Avg
4.95
Market Cap
$192.49M
Quick Ratio (Acid-Test)
3.61
TTM Avg
10.13
3Y Avg
8.61
5Y Avg
9.32
Market Cap
$205.80M
Quick Ratio (Acid-Test)
17.38
TTM Avg
6.77
3Y Avg
6.87
5Y Avg
6.33
Market Cap
$190.07M
Quick Ratio (Acid-Test)
4.82
TTM Avg
7.13
3Y Avg
7.35
5Y Avg
8.24
Market Cap
$207.27M
Quick Ratio (Acid-Test)
2.45
TTM Avg
2.08
3Y Avg
1.84
5Y Avg
1.77
Market Cap
$189.11M
Quick Ratio (Acid-Test)
7.90
TTM Avg
9.91
3Y Avg
10.86
5Y Avg
18.34
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | $198.33M | 7.48 | 9.56 | 7.55 | 6.18 |
| Exagen Inc. (XGN)vs › | $197.87M | 3.18 | 3.08 | 4.43 | 6.31 |
| Surrozen, Inc. (SRZN)vs › | $197.18M | 12.14 | 7.27 | 7.16 | 7.21 |
| Alector, Inc. (ALEC)vs › | $200.96M | 5.26 | 3.62 | 4.54 | 4.95 |
| RxSight, Inc. (RXST)vs › | $192.49M | 3.61 | 10.13 | 8.61 | 9.32 |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | 17.38 | 6.77 | 6.87 | 6.33 |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | 4.82 | 7.13 | 7.35 | 8.24 |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 2.45 | 2.08 | 1.84 | 1.77 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | 7.90 | 9.91 | 10.86 | 18.34 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
Quick Ratio
7.48
Excludes inventory
Current Ratio
7.48
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 7.48 |
| 2026-03-31 | 7.65 |
| 2025-12-31 | 8.65 |
| 2025-09-30 | 10.67 |
| 2025-06-30 | 13.33 |
| 2025-03-31 | 12.34 |
| 2024-12-31 | 9.43 |
| 2024-09-30 | 10.70 |
| 2024-06-30 | 4.78 |
| 2024-03-31 | 3.03 |
| 2023-12-31 | 1.33 |
| 2023-09-30 | 4.51 |
| 2023-06-30 | 4.18 |
| 2023-03-31 | 5.22 |
| 2022-12-31 | 5.91 |
| 2022-09-30 | 6.73 |
| 2022-06-30 | 5.11 |
| 2022-03-31 | 3.31 |
| 2021-12-31 | 2.00 |
| 2021-09-30 | 1.59 |
| 2021-06-30 | 1.91 |
| 2021-03-31 | 1.93 |
| 2020-12-31 | 1.86 |
| 2020-09-30 | 2.16 |
| 2020-06-30 | 2.71 |
| 2020-03-31 | 2.48 |
| 2019-12-31 | 2.77 |
| 2019-09-30 | 1.23 |
| 2019-06-30 | 1.39 |
| 2019-03-31 | 1.80 |
| 2018-12-31 | 1.20 |
| 2018-09-30 | 1.60 |
| 2018-06-30 | 4.96 |
| 2018-03-31 | 7.20 |
| 2017-12-31 | 9.18 |
| 2017-09-30 | 9.48 |
| 2017-06-30 | 5.71 |
| 2017-03-31 | 5.37 |
| 2016-12-31 | 6.33 |
| 2016-09-30 | 10.84 |
| 2016-06-30 | 9.96 |
| 2016-03-31 | 4.73 |
| 2015-12-31 | 5.34 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
